Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.

Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA.

Ann Oncol. 2013 May;24(5):1262-6. doi: 10.1093/annonc/mds617. Epub 2012 Dec 17.

2.

Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.

Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA.

Ann Oncol. 2013 Nov;24(11):2854-9. doi: 10.1093/annonc/mdt340. Epub 2013 Aug 29.

3.

Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.

Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA.

Oncology. 2012;83(5):300-4. doi: 10.1159/000341353. Epub 2012 Sep 4.

4.

Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.

Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA.

Cancer. 2010 Oct 1;116(19):4487-94. doi: 10.1002/cncr.25431.

5.

Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG.

Ann Oncol. 2012 Oct;23(10):2638-42. Epub 2012 Jul 24.

6.

Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.

Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA.

Cancer. 2005 Dec 1;104(11):2365-72.

7.

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG.

Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.

8.

Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.

Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA.

J Clin Oncol. 2006 Aug 20;24(24):3953-8.

9.

Cancer of the gastroesophageal junction: combined modality therapy.

Ilson DH.

Surg Oncol Clin N Am. 2006 Oct;15(4):803-24. Review.

PMID:
17030275
10.

Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.

Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA.

Cancer. 2004 Jun 1;100(11):2347-54.

11.

Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.

J Clin Oncol. 2010 Nov 1;28(31):4714-21. doi: 10.1200/JCO.2010.30.7702. Epub 2010 Sep 27.

12.

Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.

Molena D, Sun HH, Badr AS, Mungo B, Sarkaria IS, Adusumilli PS, Bains MS, Rusch VW, Ilson DH, Rizk NP.

Dis Esophagus. 2014 May-Jun;27(4):355-9. doi: 10.1111/dote.12126. Epub 2013 Aug 29.

PMID:
24033404
13.

Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders.

Cerfolio RJ, Bryant AS, Talati AA, Eloubeidi MA, Cerfolio RM, Winokur TS.

J Thorac Cardiovasc Surg. 2009 Mar;137(3):605-9. doi: 10.1016/j.jtcvs.2008.11.016. Erratum in: J Thorac Cardiovasc Surg. 2009 Jun;137(6):1581. Eloubeidi, Mohamad A [added].

14.

Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.

Spizzo G, Öfner D, de Vries A, Lukas P, Steger G, Pluschnig U, Zacherl J, Widder J, Zabernigg A, Gastl G, Mühlmann G.

Ann Surg Oncol. 2011 Mar;18(3):677-83. doi: 10.1245/s10434-010-1388-2. Epub 2010 Nov 10.

PMID:
21063792
15.

The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.

Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA.

Oncology. 2010;78(5-6):316-22. doi: 10.1159/000319938. Epub 2010 Aug 11.

PMID:
20699623
16.

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.

Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA.

Cancer. 2001 Jul 15;92(2):279-86.

PMID:
11466680
17.

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW.

J Clin Oncol. 2005 Feb 20;23(6):1237-44.

18.

Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.

Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA.

Cancer. 2006 Feb 1;106(3):552-8.

19.

Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.

Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA.

J Clin Oncol. 2006 Jan 10;24(2):259-67. Epub 2005 Dec 12.

20.

The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.

van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH.

J Nucl Med. 2016 May;57(5):691-700. doi: 10.2967/jnumed.115.163766. Epub 2016 Jan 21.

PMID:
26795288
Items per page

Supplemental Content

Write to the Help Desk